Caffeine for preterm infants: Fixed standard dose, adjustments for age or high dose?
- PMID: 33168464
- PMCID: PMC8096613
- DOI: 10.1016/j.siny.2020.101178
Caffeine for preterm infants: Fixed standard dose, adjustments for age or high dose?
Abstract
Caffeine is an effective treatment for apnea of prematurity and has several important benefits, including decreasing respiratory morbidity and motor impairment. In this article, we focus on the dose of caffeine. We review the evidence regarding the efficacy and safety of standard caffeine dosing and alternative dosing approaches, including the use of high dose caffeine and routine dose adjustments for age. Current evidence suggests high dose caffeine may provide additional benefit in reducing the risk of bronchopulmonary dysplasia and extubation failure, but may also increase the risk of cerebellar hemorrhage and seizures. Increasing the standard caffeine citrate dose every 1-2 weeks to a goal dose of 8 mg per kilogram every 24 h may help maintain therapeutic effect. We conclude by highlighting the need for additional trials before high dose caffeine is routinely used.
Keywords: Apnea; Caffeine; Infant; Neonate; Pharmacokinetics; Preterm.
© 2020 Published by Elsevier Ltd.
Conflict of interest statement
References
-
- Eichenwald EC, American Academy of Pediatrics Committee on Fetus and Newborn. Apnea of Prematurity. Pediatrics. 2016;137(1).
-
- Aranda JV, Gorman W, Bergsteinsson H, Gunn T. Efficacy of caffeine in treatment of apnea in the low-birth-weight infant. The Journal of pediatrics. 1977;90(3):467–472. - PubMed
-
- Mitenko PA, Ogilvie RI. Rational intravenous doses of theophylline. The New England journal of medicine. 1973;289(12):600–603. - PubMed
-
- Aranda JV, Cook CE, Gorman W, et al. Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. The Journal of pediatrics. 1979;94(4):663–668. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
